EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Percutaneous Repair of Moderate-to-Severe or Severe Functional Mitral Regurgitation in Patients with Symptomatic Heart Failure: Baseline Characteristics of Patients in the RESHAPE-HF2 Trial and Comparison to COAPT and MITRA-FR Trials

Stefan D Anker, Tim Friede, Ralph Stephan von Bardeleben, Javed Butler, Muhammad Shahzeb Khan, Monika Diek, Jutta Heinrich, Martin Geyer, Marius Placzek, Roberto Ferrari, William T Abraham, Ottavio Alfieri und 45 weitere

European Journal of Heart Failure · 2024

DOI: 10.1002/ejhf.3286 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Stefan D Anker und 56 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology (CVK) of German Heart Center Charité; Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardio…. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Heart Failure, Severity of Illness Index, Stroke Volume. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Abbott Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The RESHAPE-HF2 trial is designed to assess the efficacy and safety of the MitraClip device system for the treatment of clinically important functional mitral regurgitation (FMR) in patients with heart failure (HF). This report describes the baseline characteristics of patients enrolled in the RESHAPE-HF2 trial compared to those enrolled in the COAPT and MITRA-FR trials. Methods and results The RESHAPE-HF2 study is an investigator-initiated, prospective, randomized, multicentre trial including patients with symptomatic HF, a left ventricular ejection fraction (LVEF) between 20% and 50% with moderate-to-severe or severe FMR, for whom isolated mitral valve surgery was not recommended. Patients were randomized 1:1 to a strategy of delivering or withholding MitraClip. Of 506 patients randomized, the mean age of the patients was 70 ± 10 years, and 99 of them (20%) were women. The median EuroSCORE II was 5.3 (2.8–9.0) and median plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 2745 (1407–5385) pg/ml. Most patients were prescribed beta-blockers (96%), diuretics (96%), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors (82%) and mineralocorticoid receptor antagonists (82%). The use of sodium–glucose cotransporter 2 inhibitors was rare (7%). Cardiac resynchronization therapy (CRT) devices had been previously implanted in 29% of patients. Mean LVEF, left ventricular end-diastolic volume and effective regurgitant orifice area (EROA) were 31 ± 8%, 211 ± 76 ml and 0.25 ± 0.08 cm2, respectively, whereas 44% of patients had mitral regurgitation severity of grade 4+. Compared to patients enrolled in COAPT and MITRA-FR, those enrolled in RESHAPE-HF2 were less likely to have mitral regurgitation grade 4+ and, on average, HAD lower EROA, and plasma NT-proBNP and higher estimated glomerular filtration rate, but otherwise had similar age, comorbidities, CRT therapy and LVEF.

Conclusion

Patients enrolled in RESHAPE-HF2 represent a third distinct population where MitraClip was tested in, that is one mainly comprising of patients with moderate-to-severe FMR instead of only severe FMR, as enrolled in the COAPT and MITRA-FR trials. The results of RESHAPE-HF2 will provide crucial insights regarding broader application of the transcatheter edge-to-edge repair procedure in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral Valve InsufficiencyHeart FailureSeverity of Illness IndexStroke VolumeHumansFemaleMaleAgedProspective StudiesTreatment OutcomeMiddle AgedPeptide FragmentsMitral ValveNatriuretic Peptide, BrainHeart Valve Prosthesis ImplantationVentricular Function, Left

Stichwörter der Autor:innen

MitraClipMitral regurgitationTranscatheter edge‐to‐edge repair

Substanzen

pro-brain natriuretic peptide (1-76)Peptide FragmentsNatriuretic Peptide, Brain

Autor:innen und Institutionen

  • Department of Cardiology (CVK) of German Heart Center Charité; Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedi…
  • Department of Cardiology and Pneumology, University Medical Centre Göttingen, Georg August University of Göttingen, Göttingen, Germany.
  • German Centre for Cardiovascular Research (DZHK), Partner Site Göttingen, Göttingen, Germany.
  • Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.
  • German Centre for Cardiovascular Research (DZHK), partner site Göttingen, Göttingen, Germany.
  • Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.

Förderung

  • Abbott Fund

Zitieren

APA

Anker, S. D., Friede, T., von Bardeleben, R. S., Butler, J., Khan, M. S., Diek, M., Heinrich, J., Geyer, M., Placzek, M., Ferrari, R., Abraham, W. T., Alfieri, O., Auricchio, A., Bayes-Genis, A., Cleland, J. G. F., Filippatos, G., Gustafsson, F., Haverkamp, W., Kelm, M., …, & Ponikowski, P. (2024). Percutaneous Repair of Moderate-to-Severe or Severe Functional Mitral Regurgitation in Patients with Symptomatic Heart Failure: Baseline Characteristics of Patients in the RESHAPE-HF2 Trial and Comparison to COAPT and MITRA-FR Trials. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3286

Vancouver

Anker SD, Friede T, von Bardeleben RS, Butler J, Khan MS, Diek M, et al. Percutaneous Repair of Moderate-to-Severe or Severe Functional Mitral Regurgitation in Patients with Symptomatic Heart Failure: Baseline Characteristics of Patients in the RESHAPE-HF2 Trial and Comparison to COAPT and MITRA-FR Trials. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3286

BibTeX
@article{Anker2024,
  author = {Anker, Stefan D and Friede, Tim and von Bardeleben, Ralph Stephan and Butler, Javed and Khan, Muhammad Shahzeb and Diek, Monika and Heinrich, Jutta and Geyer, Martin and Placzek, Marius and Ferrari, Roberto and Abraham, William T and Alfieri, Ottavio and Auricchio, Angelo and Bayes-Genis, Antoni and Cleland, John G F and Filippatos, Gerasimos and Gustafsson, Finn and Haverkamp, Wilhelm and Kelm, Malte and Kuck, Karl-Heinz and Landmesser, Ulf and Maggioni, Aldo P and Metra, Marco and Ninios, Vlasis and Petrie, Mark C and Rassaf, Tienush and Ruschitzka, Frank and Schäfer, Ulrich and Schulze, P Christian and Spargias, Konstantinos and Vahanian, Alec and Zamorano, Jose Luis and Zeiher, Andreas and Karakas, Mahir and Koehler, Friedrich and Lainscak, Mitja and Öner, Alper and Mezilis, Nikolaos and Theofilogiannakos, Efstratios K and Ninios, Ilias and Chrissoheris, Michael and Kourkoveli, Panagiota and Papadopoulos, Konstantinos and Smolka, Grzegorz and Wojakowski, Wojciech and Reczuch, Krzysztof and Pinto, Fausto J and Zmudka, Krzysztof and Kalarus, Zbigniew and Adamo, Marianna and Santiago-Vacas, Evelyn and Ruf, Tobias Friedrich and Gross, Michael and Tongers, Joern and Hasenfuß, Gerd and Schillinger, Wolfgang and Ponikowski, Piotr},
  title = {Percutaneous Repair of Moderate-to-Severe or Severe Functional Mitral Regurgitation in Patients with Symptomatic Heart Failure: Baseline Characteristics of Patients in the RESHAPE-HF2 Trial and Comparison to COAPT and MITRA-FR Trials},
  journal = {European Journal of Heart Failure},
  year = {2024},
  doi = {10.1002/ejhf.3286}
}
Kostenlos starten →